PTAB Litigation Blog
  • Home
  • Cookie Policy
  • About
  • Advanced Topics
  • Contributors
  • Contacts
  • Design Patents
  • Discovery
  • District Court
  • Joinder
Select Page
Subsequent Challenge Does Not Justify Discretionary Denial

Subsequent Challenge Does Not Justify Discretionary Denial

by Matthew Johnson | Aug 8, 2025 | PGR, PTAB News, PTAB Trial Basics, Trial Institution

By Evan Tassis and Matt Johnson – In a recent decision, Acting Director Coke Morgan Stewart denied a Patent Owner’s request for discretionary denial in LifeVac, LLC v. DCSTAR, Inc., IPR2025-00454.  Even though Petitioner had previously challenged the same patent...
Acting Director Clarifies Multi-Petition Policy for Competing Constructions

Acting Director Clarifies Multi-Petition Policy for Competing Constructions

by Matthew Johnson | Aug 5, 2025 | Claim Construction, PTAB News, PTAB Trial Basics, Trial Institution

By Levent Herguner and Matt Johnson – On June 25, 2025, Acting Director Coke Stewart released an informative decision vacating institution of inter partes review (“IPR”) based on two petitions that were primarily filed to present two different constructions....
“Settled-Expectations” Analysis May Leave Some Petitioners Feeling Unsettled

“Settled-Expectations” Analysis May Leave Some Petitioners Feeling Unsettled

by Matthew Johnson | Jul 23, 2025 | PTAB News, PTAB Trial Basics, Trial Institution

By Sue Gerber and Matt Johnson – As discretionary denials are on the rise and institution rates are declining at the PTAB (link), recent decisions from the PTAB have introduced the notion of a patent owner’s “settled expectations” as another reason for the PTAB...
Discretionary Denial Where Inventors Petitioned for Unpatentability

Discretionary Denial Where Inventors Petitioned for Unpatentability

by Matthew Johnson | Jul 18, 2025 | PTAB News, PTAB Trial Basics, Trial Institution

By Hannah Mehrle and Matt Johnson – Coke Morgan Stewart, the acting director of the United States Patent and Trademark Office (“USPTO”), exercised discretion under 35 U.S.C. § 314(a) to deny Tessell’s (“Petitioner’s”) petition in favor of Nutanix (“Patent...
Discretionary Denial of IPR Institution Due to Advanced Hatch-Waxman Litigation

Discretionary Denial of IPR Institution Due to Advanced Hatch-Waxman Litigation

by Matthew Johnson | Jul 16, 2025 | Pharmaceutical, PTAB News, PTAB Trial Basics, Trial Institution

By Nicole Prescott,* Phillip Shelton, and Matt Johnson – In a recent decision, the Patent Trial and Appeals Board (“PTAB”) exercised its discretion under 35 U.S.C. § 314(a) to deny institution of an inter partes review (“IPR”) after applying the Fintiv factors,...
Physical Products Cannot Form Basis of an IPR

Physical Products Cannot Form Basis of an IPR

by Carl Kukkonen | Jul 9, 2025 | Prior Art Issues, PTAB News, PTAB Trial Basics, Trial Institution

By Carl Kukkonen – On May 1, 2025, the Patent Trial and Appeal Board (PTAB) denied institution of inter partes review (IPR) of U.S. Patent No. 11,140,841 in the case of Aardevo North America, LLC v. Agventure B.V. The patent in question, owned by Agventure,...
« Older Entries

About this blog

Categories

  • 325(d) issues
  • Amendment Practice
  • CBMs
  • Claim Construction
  • Design Patents
  • Discovery
  • District Court
  • Estoppel
  • Evidentiary Issues
  • Expert Witnesses
  • Federal Circuit
  • Federal Circuit Appeal
  • Final Written Decisions
  • Joinder
  • Motions Practice
  • Other News
  • Patent Eligible Subject Matter
  • Petitions
  • PGR
  • Pharmaceutical
  • Preliminary Responses
  • Prior Art Issues
  • PTAB News
  • PTAB Trial Basics
  • Real Party in Interest
  • Request for Reconsideration
  • Standing
  • Stay
  • Time Limits
  • Trial Institution
  • Uncategorized

Archives

Links

www.jonesday.com

About Jones Day's Intellectual Property Practice

Subscribe to Jones Day publications

    • Privacy
    • X
    • RSS

    The opinions expressed are those of the authors and do not necessarily reflect the views of Jones Day or its clients. The posts and information provided are for general information purposes and are not intended to be and should not be taken as legal advice.